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 2 
Abstract  1 
Circulating tumour DNA (ctDNA) detection and monitoring has enormous potential 2 
clinical utility in oncology. We describe here a fast, flexible and cost-effective method 3 
to profile multiple genes simultaneously in low input cell-free DNA (cfDNA): Next 4 
Generation-Targeted Amplicon Sequencing (NG-TAS). We designed a panel of 377 5 
amplicons spanning 20 cancer genes and tested the NG-TAS pipeline using cell-free 6 
DNA from two hapmap lymphoblastoid cell lines. NG-TAS consistently detected 7 
mutations in cfDNA when mutation allele fraction was >1%. We applied NG-TAS to a 8 
clinical cohort of metastatic breast cancer patients, demonstrating its potential in 9 
monitoring the disease. The computational pipeline is available at: 10 
https://github.com/cclab-brca/NGTAS_pipeline. 11 
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 3 
BACKGROUND 1 
Cell free DNA (cfDNA) in plasma was first analysed in cancer patients nearly 50 2 
years ago [1]. A fraction of cfDNA was shown to carry mutations found in the matched 3 
tumour, and designated circulating tumour DNA (ctDNA) [1–3]. The utility of ctDNA as 4 
a non-invasive diagnostic, prognostic or predictive biomarker in human cancer is now 5 
well documented [4–8]. 6 
The amount of cfDNA in plasma is usually low and the ctDNA fraction is typically 7 
only 1-30%, hence low mutant allele frequencies have to be detected. Human cancers 8 
are genetically heterogeneous and mutations occur infrequently at recurrent hotspots. 9 
Therefore, in most clinical scenarios (e.g. early diagnosis or monitoring of tumour 10 
evolution), high sensitivity and the simultaneous investigation of multiple gene targets 11 
are desirable features of any ctDNA detection and quantitation method.  12 
There are a range of methods for detecting mutations in ctDNA, with the target 13 
varying from a single nucleotide variant (SNV) to the whole genome. A widely used 14 
method to detect mutations in ctDNA is digital polymerase chain reaction (dPCR) 15 
performed in microfluidic devices or water-in-oil droplet emulsions [9,10]. Whilst dPCR 16 
is able to detect rare mutations with extremely high sensitivity, it is restricted by the 17 
number of targets that can be examined in a single reaction [11] . 18 
Several sequencing based approaches have been developed to incorporate 19 
multiple genomic loci, enabling de novo mutation identification in ctDNA. Previously, 20 
we described Targeted Amplicon Sequencing (TAm-Seq), which utilised 48 primer 21 
pairs to identify mutations in hotspots or selected regions of 6 key driver genes [12].  22 
While TAm-Seq is useful, it is limited to a small number of targets. Capture based 23 
sequencing methods can cover a larger number of genes (or the whole exome), but 24 
are costly at the sequencing coverage (>300) required to detect allele frequencies 25 
~1%.  26 
There several ready to use commercial kits for ctDNA sequencing, which can cover 27 
up to hundreds of mutation hotspots and many genes. These include InvisionTM 28 
(Inivata), OncomineTM cfDNA assay (Thermo Fisher Scientific), Guardant360TM 29 
(Guardant Health), and PlasmaSELECT™ (Personal Genome Diagnostics). These 30 
products are expensive and test custom gene panels. Disturbingly, a recent study 31 
comparing the performance of two of these commercial products (Guardant360TM and 32 
PlasmaSELECTTM) in a cohort of plasma samples from prostate cancer patients, 33 
revealed poor agreement [13].   34 
Recently unique molecular barcodes have been developed to tag each cfDNA 35 
template molecule before PCR amplification in order to reduce the error rate and allow 36 
robust detection of rare mutant alleles in ctDNA [14]. 37 
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 4 
In summary, using current ctDNA profiling methodology, the detection of mutations 1 
in a good number of cancer genes with sufficient sensitivity and in a cost-effective way 2 
poses significant challenges. Here we describe a new method for the profiling of 3 
ctDNA, designated Next Generation-Targeted Amplicon Sequencing (NG-TAS), with 4 
several unique features: i) optimised for low input ctDNA; ii) high level of multiplexing, 5 
enabling the analyses of multiple gene targets; iii) a bespoke computational pipeline 6 
for data analysis; and iv) very competitive costing. NG-TAS is designed to be flexible 7 
in terms of choice of gene targets and regions of interest; thus, it can be tailored to 8 
various cancer types and clinical contexts. 9 
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METHODS  1 
Patient samples and blood processing 2 
Patients were recruited from 3 different centres including Cambridge University 3 
Hospital, Netherland Cancer Institute (NKI) and Vall d’Hebron Institute of Oncology 4 
(VHIO). Metastatic breast cancer patients with hormone receptor positive tumours 5 
were recruited as a part of a clinical trial (patient number = 30, plasma samples number 6 
= 366). Blood samples were collected in EDTA tubes and processed within one hour 7 
to prevent lymphocyte lysis and fragmentation. Samples were centrifuged at 820g for 8 
10min at room temperature to separate the plasma from the peripheral blood cells. 9 
The plasma was further centrifuged at 1400g for 10min to remove remaining cells and 10 
cell debris. The plasma was stored at -80°C until DNA extraction. This study was 11 
approved by the regulatory and ethic committees at each site and the reference 12 
number is NCT02285179 (https://clinicaltrials.gov/ct2/show/NCT02285179). All 13 
human samples used were collected after informed consent, and the study was fully 14 
compliant with the Helsinki Declaration 15 
 16 
DNA extraction from plasma and buffy coat 17 
Plasma DNA was extracted from between 2-4 ml of plasma with the QiaSymphony 18 
according to the manufacturer’s instruction using Qiagen circulating DNA extraction 19 
kit. DNA was isolated from the buffy coat samples using DNeasy Blood & Tissue Kits 20 
(Qiagen).  21 
 22 
Generation of cfDNA from NA12878 and NA11840 23 
As previously reported [15] two lymphoblastoid cell lines, NA12878 and NA11840 from 24 
Human Genome Diversity Project (HGDP)-CEPH collection were obtained from the 25 
Coriell Cell Repository. A catalogue of highly accurate whole genome variant calls and 26 
homozygous reference calls has been derived for sample NA12878 by integrating 27 
independent sequencing data and the results of multiple pipelines 28 
(http://www.illumina.com/platinumgenomes). NA11840 cell line was chosen from a set 29 
of 17 available CEPH cell lines in our laboratory as it shared the least number of SNPs 30 
with NA12878, to generate the maximum number of virtual somatic SNVs. 31 
The cell lines were grown as suspension in RPMI 1640-Glutamax (Invitrogen) 32 
supplemented with 10% foetal calf serum, 5% penicillin and streptomycin at 37°C and 33 
5% CO2.  The media that the cell lines were grown in were collected when cells were 34 
passaged.  The media were centrifuged at 1500rpm for 10 minutes at 4oC to remove 35 
cells and cellular debris.  The clarified media were stored at -20oC until required. Cell-36 
free DNA was extracted from the thawed media using the Qiagen circulating DNA 37 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
extraction kit (Qiagen) according to the manufacturer’s instructions and quantified 1 
using Qubit High Sensitivity DNA quantification kit (Life Technologies). DNA from both 2 
cell lines was diluted to obtain 50 ng/μl stock concentrations. To generate the serial 3 
dilutions of one cell line with the other, we mixed by volume to obtain the percentage 4 
(volume/volume) as presented in Additional file 1: Table S1 (n=12).    5 
Platinum variant calls for sample NA12878 (the virtual ‘tumour’) and confident regions 6 
(high confidence homozygous reference regions plus platinum calls) [16] were 7 
downloaded from http://www.illumina.com/platinumgenomes. Genotype data for 8 
sample NA11840 (the virtual ‘normal’) was obtained from the 1000 Genomes website. 9 
Platinum calls were intersected with our NG-TAS panel target regions and variants 10 
shared with the NA11840 sample were excluded. Five platinum calls were covered 11 
theoretically by our NG-TAS panel; however, one was targeted by one of the amplicons 12 
showing no coverage, therefore 4 SNVs were considered as identifiable ‘somatic 13 
variants’. 14 
 15 
NGS library construction 16 
NGS libraries were prepared from 3-5 ng of cfDNA using the ThruPLEX® Plasma-seq 17 
kit (Rubicon Genomics, USA) as described in the manufacturer’s instructions. NGS 18 
library was quantified using qPCR KAPA Library Quantification kit (KAPA Biosystem), 19 
while the fragment size and the NGS library yield were measured with 2200 20 
TapeStation instrument (Agilent).  21 
 22 
Digital PCR 23 
BioMark system from Fluidigm has been used for dPCR, and the analyses have been 24 
performed as previously described [17]. As described in manufacturer’s instructions, 25 
DNA samples were mixed with 2X TaqMan® Gene Expression Master Mix (Life 26 
Technology, 4369016), 20X GE Sample Loading Reagent (Fluidigm, 85000746) and 27 
20X gene-specific assays. The reaction mix were loaded on the qdPCR 37KTM IFC 28 
(Fluidigm, 100-6152). For KRAS (G13D) and AKT1 (E17K) mutant and wild type 29 
PrimePCRTM ddPCRTM Mutation Assays were obtained from Bio-Rad 30 
(dHsaCP2000013 and dHsaCP2000014, dHsaCP2000032 and dHsaCP2000031 31 
respectively). The PIK3CA and ESR1 probes and primers were previously described 32 
[7,18], and the primer and probes used are listed in Additional file 1: Table S2. 33 
 34 
NG-TAS protocol 35 
Primer design for NG-TAS 36 
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Primers were designed with NCBI Primer-BLAST tool with Tm range of 59-61°C. The 1 
universal primer sequences (CS1 and CS2) were added at the 5’ end of the designed 2 
primers. All primer pairs were tested alone and in multiplexed PCR reactions using 10 3 
ng of TaqMan® Control Human Genomic DNA (Thermo Fisher Scientific) in 10 μl 4 
reaction volumes. The coverage and performance of primers were analysed using 5 
2200 TapeStation instrument (Agilent) and Hi-seq 4000. The primers were grouped 6 
together as 7-8plex, and primers in each group were chosen to target different genes 7 
in order to minimise non-specific amplification and cross-reactivity. 8 
 9 
Access Array™ microfluidic system 10 
The 377 pairs of optimised primers were divided into 48 wells, with each well containing 11 
7-8 pairs of primers for multiplexed PCR. Primers were diluted to the final concentration 12 
of 1 μM to make 20X primer solution. 4μl of the 20X primer solution from the 48 wells 13 
were added to the primer inlets of the Access Array™ IFC (Fluidigm). For the sample 14 
inlets, pre-sample master mix consisted of 2X Master Mix (Qiagen, 206143), 5X Q-15 
solution, 20X Access Array™ Loading Reagent (Fluidigm), and DNA sample were 16 
added. The loaded IFC then moved to FC1™ Cycler (Fluidigm) for thermal cycles: 17 
95°C for 15min, 30 cycles of 94°C for 30sec, 59°C for 90sec, 72°C for 90sec, and final 18 
extension step 60°C for 30min. The reaction products were harvested using Post-PCR 19 
IFC controller as described in manufacturer’s instructions.  20 
The harvested product was diluted (1:10) with water for further barcoding PCR. 21 
Barcoding PCR reaction master mix contains 2X Master Mix (Qiagen), diluted 22 
harvested product from Access Array™, and Access Array™ Barcode Library for 23 
Illumina® Sequencers single direction for barcoding primers (Fluidigm, 100-4876). The 24 
thermal cycle for barcoding is: 95°C for 10min, 15 cycles of 95°C for 15sec, 60°C for 25 
30sec, 72°C for 1min, and final extension step of 72°C for 3min. The PCR reaction 26 
was performed using T100™ Thermal Cycler (Bio-Rad). 27 
 28 
Quantification and clean-up of barcode Access Array™ harvest 29 
After barcoding PCR, all samples were analysed using 2200 TapeStation (Agilent) to 30 
measure the concentration and size of the products (average 260bp). The PCR 31 
products were pooled and cleaned with AMPure XP beads (Beckman Coulter, A63880) 32 
following the manufacturer’s instruction. Briefly, the samples were mixed with the 33 
magnetic beads to the ratio of 180:100 in volume. The beads were washed twice with 34 
80% ethanol and dried by incubating at 30°C for 10min. Then the beads were eluted 35 
with water and the cleaned PCR product was run on the E-Gel® 2% agarose gel 36 
(Thermo Fisher Scientific, G501802) for further size selection and extraction. The band 37 
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 8 
between 200-300bp was cut out and DNA was isolated from the gel using the QIAquick 1 
Gel Extraction kit (Qiagen, 28704), and 10-20nM of the eluents was submitted for 2 
paired-end Hi-seq 4000 for sequencing. 3 
 4 
Analysis of NG-TAS data  5 
Quality control, alignment and bam files annotation 6 
For each sequencing lane, quality control of raw data was performed using FastQC 7 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Up to 384 samples were 8 
multiplexed in a single sequencing lane and demultiplexing was performed using in-9 
house software. 10 
Alignment, read trimming (at 80bp) and base quality recalibration was performed in a 11 
single step using Novoalign (v 3.08). However, to facilitate a broad use of the pipeline, 12 
a version using BWA-MEM is also available. Alignment and bam metrics were 13 
computed using Picard Tools (v 2.17). To remove potential off-target PCR products, 14 
only reads mapped in proper pair and with insert size > 60bp were retained. After this 15 
filtering, bam files were locally realigned using the Genome Analysis Toolkit (GATK, v 16 
3.6). Reads were then assigned to the amplicon they belonged to using a custom java 17 
script, in order to enable a per amplicon coverage and mutation calling analysis. 18 
Coverage was computed for each amplicon in each sample using a custom java/R 19 
script. One amplicon (SF3B1_D0069_001) showed an extremely high rate of 20 
mismatches and indels in all the analysed samples, therefore we excluded it from 21 
downstream analyses. 22 
 23 
Mutation calling 24 
Mutation calling was run separately for each amplicon in the panel. The core mutation 25 
calling was performed for each pair of plasma and normal samples (or NA12878 an 26 
NA11849 from the dilution series) using Mutect2 (included in GATK 3.6). The 27 
minPruning parameter was set at 5 to reduce computational time with no significant 28 
impact on the results. Besides the set of mutations passing all internal filters, we 29 
included those failing the following internal filters or a combination of them: 30 
"alt_allele_in_normal", "clustered_events", "homologous_mapping_event", 31 
"multi_event_alt_allele_in_normal". On this set of candidate mutations, we applied the 32 
following filtering criteria: coverage in normal and plasma >100x, alternative allele in 33 
normal <1% and plasma/normal VAF ratio >5. The core mutation calling was repeated 34 
for the three replicates generated for each pair and only mutations called in at least 35 
two replicates were retained. For this set of mutations, we run HaplotypeCaller 36 
(included in GATK 3.6) to compute the average VAF across the three replicates and 37 
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 9 
filter out mutations with an average VAF<1% and an average plasma/normal ratio <5 1 
(Figure 4A). An extra filter was introduced for FFPE samples, where C>T and G>A 2 
transitions with VAF<15% were filtered out because likely to be consequence of 3 
cytosine deamination caused by fixation. 4 
In calling somatic mutations from set of longitudinal samples from the same patient, 5 
we first repeated the above procedure for all samples. Then, HaplotypeCaller was run 6 
again to estimate in all samples the coverage and VAF of each mutation called in at 7 
least one of them. This was followed by a variant annotation step using Annovar. 8 
Finally, results obtained for all amplicons were merged to generate a single vcf file. A 9 
final filter was applied at group level, that is, keeping only mutations that at least in one 10 
sample had VAF higher than 5% (Additional file 1: Fig. S1). 11 
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RESULTS 1 
Optimising targeted deep sequencing in cfDNA by NG-TAS 2 
We designed 377 pairs of primers covering all exons or hotspots of 20 genes 3 
commonly mutated in breast cancer (Table 1). To identify the genes or hotspots of 4 
interest, we primarily looked at the comprehensive study carried out in our lab (Pereira 5 
et al. Nat Comm 2016). Other genes genes (e.g. ESR1) were included because 6 
reported as frequently mutated in metastasis [19]. Since the average cfDNA fragment 7 
size is 160-170bp, NG-TAS primers were designed to generate amplicons of 69-157bp 8 
(Additional file 2).  9 
In a preliminary optimization step, individual primer pairs were tested in conventional 10 
single and multiplexed (7-8plex) PCR reactions.  The NG-TAS experimental workflow 11 
(Figure 1A), starts with a multiplexed PCR step (7-8 primer pairs) performed using 12 
Access Array™, a microfluidic system from Fluidigm.  Each multiplexed reaction 13 
contained primers targeting different genes to minimise the generation of unwanted 14 
PCR products.  The multiplexed PCR products were assessed using the Bioanalyser 15 
and 2200 TapeStation instrument (Agilent Genomics; Additional file 1: Fig. S2). 16 
Multiplexed PCR products were then pooled and barcoded with 384 unique barcodes 17 
in a second PCR reaction.  Barcoded products were pooled, and size selected to 18 
remove primer dimers before submission for NGS paired-end 150bp sequencing.    19 
 Raw sequencing data were aligned and processed as described in Figure 1B and 20 
Methods. Specific filters were applied to exclude reads from primer dimers or other 21 
PCR artefacts. Since the amplicons are partially overlapping, each read was assigned 22 
to its respective amplicon, to enable a per-amplicon analysis for coverage estimation 23 
and mutation calling.  24 
To optimise NG-TAS we used cfDNA isolated from the culture media of the Platinum 25 
Genome Hapmap NA12878 cell line. The size profile of cfDNA isolated from the tissue 26 
culture media was similar to that of plasma cfDNA (Additional file 1: Fig. S3). We tested 27 
a range of input cfDNA amounts with NG-TAS (0.016 ng to 50 ng) in 4 replicates for 28 
each input. For each cfDNA input we tested: i) a pre-amplification step and ii) the use 29 
of the Qiagen Q solution. To assess the data generated the percentage of aligned 30 
sequencing reads was computed (Figure 2A). In the TAM-Seq protocol addition of a 31 
pre-amplification step reduced the probability of nonspecific amplification and biased 32 
coverage [12]. However, using NG-TAS the pre-amplification step reduced the 33 
percentage of aligned reads in all cfDNA input samples tested. Hence, we eliminated 34 
pre-amplification from the NG-TAS protocol. Adding Q solution systematically 35 
increased the percentage of aligned reads, with the largest improvement observed with 36 
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0.4 and 2 ng input samples (Figure 2A). Thus, we incorporated the Q solution in all 1 
subsequent NG-TAS experiments.  2 
We then used the optimised NG-TAS protocol in triplicate experiments for each input 3 
NA12878 cfDNA (2 ng, 5 ng, and 10 ng). With 10ng of input cfDNA NG-TAS generated 4 
a median read depth of 3064x, and only 22/377 amplicons (5.8%) had coverage less 5 
than 100x (Figure 2B). In fact, high amplicon coverage was observed irrespective of 6 
amount of input cfDNA (Additional file 1: Fig. S4A and S4B). The coverage heatmap 7 
of individual amplicons showed similar patterns with 10 ng and 5 ng cfDNA input.  8 
Strong consistency was observed within each triplicate (Figure 2C). However, with 2ng 9 
cfDNA input we observed stochastic reduction in coverage for some of the amplicons. 10 
This is probably due to a reduction in template availability, with the number of 11 
amplifiable copies approaching zero for some of the amplicons.  12 
Using these data, the background noise was estimated by computing the average 13 
frequency for non-reference bases in each position, and for 99% of the targeted 14 
genomic positions background noise was 0.3% (Figure 2D). 15 
 16 
Sensitivity and specificity of mutation detection in control cfDNA 17 
To establish an analysis pipeline and assess the performance of NG-TAS, we 18 
generated a benchmark dilution series, similar to what we have previously described 19 
[15], using cfDNA collected from the tissue culture media from two lymphoblastoid cell 20 
lines from the HapMap/1000 Genome Project, NA12878 (the Platinum Genome 21 
sample) and NA11840, to mimic a tumour-normal (or plasma-normal) pair. The dilution 22 
series mixed cfDNA from NA12878 with an increasing amount of cfDNA from NA11840 23 
(from 0 to 99.8% by volume, n=12, Additional file 1: Table S1). This cfDNA dilution 24 
series was used to investigate the sensitivity in detecting mutations at high and low 25 
allele frequency (50% - 0.1%). The 377-amplicon panel encompassed four 26 
heterozygous single nucleotide polymorphisms (SNPs) present only in NA12878. 27 
These SNPs were used as “somatic” mutations for the purpose of this analysis.  28 
Using NG-TAS the cfDNA dilution series was tested in triplicate, varying the input 29 
cfDNA from 5 ng to 50 ng.  Since in clinical plasma samples the amount of ctDNA is 30 
frequently a limiting factor, we also tested the ThruPlex plasma-seq kit (requiring as 31 
little as 3 ng of cfDNA input) to generate a whole genome cfDNA library (termed NGS 32 
cfDNA library).  An aliquot of this NGS cfDNA library was then used as input for NG-33 
TAS.  34 
These NG-TAS experiments showed a strong linear relationship between the 35 
observed and expected variant allele frequencies (VAF) for the four “somatic” 36 
mutations (Table 2, Figure 3). As the input cfDNA reduced from 50 ng to 5 ng the R 37 
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squared values decreased from 0.968 to 0.885. With 10 ng input cfDNA, VAFs as low 1 
as 1% could be consistently detected. Lowering the input cfDNA generated more 2 
variable results (i.e. VAF deviating from the expected values and higher standard 3 
deviations), in particular at low AF. This is probably caused by stochastic amplification 4 
of the alternative allele. NG-TAS performed using NGS cfDNA library as input 5 
performed better than 5 ng of cfDNA input (R2=0.964, Table 2, Figure 3). 6 
The NG-TAS analysis pipeline was developed and optimised using this dilution 7 
series data and later applied to data from clinical plasma samples. As illustrated in 8 
Figure 4A and in the Methods section, mutation calling was performed using MuTect2, 9 
processing each amplicon individually. To limit the number of false positives (FPs) 10 
caused by PCR errors, we only called mutations observed in at least two out of three 11 
replicates. With the reported settings and using 10 ng of input cfDNA from the dilution 12 
series, all four SNVs were called when the expected VAF was 5% or higher, and 3 of 13 
4 SNVs when the expected VAF was 1% (Figure 4B). No FPs with VAF higher than 14 
3% were called with 50 ng and 10 ng input cfDNA from the dilution series. NG-TAS of 15 
both the 5 ng cfDNA input and NGS cfDNA library input generated seven FPs above 16 
3% in the dilution series (Figure 4C). Template scarcity and extra PCR cycles during 17 
library preparation could explain this increase in FPs. 18 
Therefore, for NG-TAS in plasma samples we recommend the use of 10 ng cfDNA 19 
per replicate as input, and a threshold of 5% VAF for de novo mutation calling. In 20 
plasma samples with less cfDNA the use of NGS cfDNA library as input for NG-TAS 21 
enables ctDNA profiling in samples with as little as 3 ng of cfDNA. However, this 22 
approach is more suitable for tracking in plasma ctDNA mutations previously identified 23 
in the tumour, rather than for de novo plasma ctDNA mutation calling. 24 
 25 
Testing NG-TAS performance in cancer patient samples 26 
We applied NGTAS to a clinical cohort of 30 metastatic breast cancer patients from 27 
which we have collected 360 plasma samples (for 31 of these NGS cfDNA library 28 
samples were used) and buffy coats. This cohort is part of a clinical trial which will be 29 
comprehensively reported in a separate manuscript (Baird et al, in preparation). 30 
To estimate the FP rate in blood samples, we used pairs of DNA extracted from the 31 
buffy coats collected at two different time points from four patients. Any mutation 32 
identified by NG-TAS in any of the eight possible buffy coat DNA pairs tested was 33 
considered a FP. Figure 5A shows that in these samples NG-TAS identified no FP with 34 
VAF greater than 5% (a result similar to NG-TAS performed using the cell line cfDNA 35 
dilution series, Figure 4C). 36 
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In 24 of the cases in our cohort, at least one tissue sample was also available and 1 
analysed. Sixteen of these cases had tissues from the primary tumour while in the 2 
remaining 8 cases, tissue samples were obtained from metastasis biopsies collected 3 
during the trial. Overall, we found at least one mutation in 21/24 patients (87.5%, Figure 4 
5B). Forty-four mutations were detected in the tissue samples and 60 in at least one 5 
plasma sample; of these, 23 were observed in both tissue and plasma. The agreement 6 
was higher for the 8 cases where a metastasis biopsy was sequenced: 7 mutations 7 
detected in the tissue, 11 detected in plasma, 7 in common (100% of tissue mutations 8 
detected in plasma). In the 16 cases where a primary tumour was tested, 33 mutations 9 
were detected in the tissue, 41 in plasma, 19 in common (58% of tissue mutations 10 
detected in plasma, Figure 5B and Additional file 1: Fig. S5). The discordance seen in 11 
this cohort is probably due to the time gap between the primary tumour tissue sample 12 
and plasma, the latter obtained when the patients had metastatic disease. In addition, 13 
most of the tissue samples were formalin-fixed paraffin-embedded (FFPE) hence, we 14 
detected an increase of C>T/G>A SNVs not usually found in ctDNA samples 15 
(Additional file 1: Fig. S5).  16 
We used dPCR to validate a subset of the mutations identified in seven patients in 17 
which NG-TAS was performed either directly on cfDNA (n=4) or using post-NGS library 18 
products (n=3).  In the four direct NG-TAS samples, four hotspot mutations PIK3CA 19 
(H1047R and E545K), KRAS (G13D), ESR1 (D538G) and AKT1 (E17K)) were all 20 
validated by dPCR. A good concordance between VAFs estimated by NG-TAS and 21 
dPCR was found (R2=0.64, Figure 5C). In the three patients where post-NGS library 22 
products was used as input, two PIK3CA hotspots (H1047R and E545K) were also 23 
validated by dPCR and a high concordance between the VAFs estimated by NG-TAS 24 
and dPCR was observed (R2=0.80, Figure 5D).  25 
 26 
Monitoring response in breast cancer patients using NG-TAS 27 
We report the example of two patients from the above clinical trial to demonstrate 28 
the use of NG-TAS for metastatic breast cancer disease monitoring. Patients had 29 
clinical monitoring performed as per the trial protocol using RECIST (Response 30 
Evaluation Criteria in Solid Tumour), version 1.1. 31 
The first patient had RECIST partial response in the first 28 weeks, and progression 32 
on day 197. NG-TAS identified mutations in GATA3 (F431fs), PIK3CA (E542K), 33 
CDKN1B (N124fs) and PTEN (137-139del) (Figure 6A). PTEN mutation VAFs in 34 
ctDNA showed parallel dynamics to RECIST: initial drop, followed by continuous rise 35 
from day 85, preceding RECIST progression by over 100 days. The VAFs of the other 36 
mutations showed a parallel rise starting later.  37 
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The second patient had stable disease by RECIST during the 60 days of available 1 
follow up. Due to limited amount of cfDNA extracted in this case, NG-TAS was 2 
performed using NGS cfDNA libraries. NG-TAS detected PIK3CA (H1047R), MAP3K1 3 
(E303fs) and TP53 (R141H and P46fs) mutations, and their VAFs showed stable 4 
values, then a slight reduction between days 20-56, followed by a slightly rise by the 5 
time monitoring was discontinued (Figure 6B).  6 
These two examples demonstrate the use of NG-TAS in plasma cfDNA samples to 7 
monitor tumour burden in metastatic breast cancer patients. 8 
 9 
Comparison of NG-TAS with other approaches 10 
We finally compared NG-TAS to other existing technologies such as digital PCR, 11 
TAm-Seq and OncomineTM Breast cfDNA Assay (Table 3). NG-TAS can be performed 12 
in 7 hours using the Fluidigm system as detailed in the methods session. Up to 384 13 
samples can be processed at the same time. Lower limits of detection can be reached 14 
using Digital PCR or Oncomine technology, however this is limited to one target for the 15 
first and a set of pre-defined hotspots for the latter. Importantly, the cost of NG-TAS, 16 
estimated at 30 GBP per sample is significantly lower than any commercial solution, 17 
making it cost-effective for use in the clinics.  18 
 19 
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DISCUSSION 1 
The genes frequently mutated in different human cancers have been characterized 2 
by large-scale sequencing studies such as The Cancer Genome Atlas [20,21]. These 3 
pan-cancer studies have revealed that most human tumours have at least 1-10 driver 4 
mutations, allowing the design of custom gene panels that could be used for generic 5 
cancer detection. But the challenge remaining is there are very few recurrent or hotspot 6 
mutations in tumours such as breast cancer, with mutations spread along the protein 7 
coding region, as observed in TP53, GATA3 and MAP3K1. Therefore, it would be 8 
desirable to cover most exons of these genes simultaneously in a ctDNA mutation 9 
detection panel. 10 
The detection of specific mutations in ctDNA is achievable by dPCR, now considered 11 
the gold standard to detect mutations with low VAFs. However, dPCR is constrained 12 
by the number of mutations that can be detected in a single reaction [11]. Thus, its 13 
high sensitivity and specificity is at the expense of the number of mutations that can 14 
be detected concurrently. At the other end of the spectrum, whole genome sequencing 15 
or whole exome sequencing suffer from reduced sensitivity at the current achievable 16 
level of sequencing depth [22]. 17 
We report here a new approach, NG-TAS, an optimised targeted amplicon 18 
sequencing pipeline that provides clinically relevant sensitivity in mutation calling 19 
across a targeted, but relatively broad and customizable panel of genes. The current 20 
version of NG-TAS covers all exons or hotspots of 20 breast cancer-associated genes 21 
in a total of 377 amplicons, has a lower detection limit of 1% VAF, and requires only 22 
three aliquots of 10 ng cfDNA input. The single step multiplexed PCR amplification 23 
makes it a less time consuming method and more cost effective than other assays, 24 
such as the commercially available Oncomine assay (Table 3). NG-TAS is flexible and 25 
custom designed primers can be adjusted to the needs of the end user, depending on 26 
the cancer type and the clinical context.  27 
Importantly, we developed a bespoke NG-TAS computational pipeline for data 28 
analysis, with all the relevant open-source code available at GitHub 29 
(https://github.com/cclab-brca/NGTAS_pipeline). All sequencing data are also made 30 
available at: https://figshare.com/articles/NGTAS_NA12878/7387370 and 31 
https://www.ebi.ac.uk (EGAS00001003392). These will be instrumental to test and 32 
further develop the computational pipeline, as required by regulatory agencies. 33 
The custom design of primers for NG-TAS is potentially challenging. Building a 34 
customised panel of primers manually, using the tool mentioned above is time-35 
consuming and, in some cases difficult due to genomic sequence context (e.g. high 36 
GC and repetitive regions). The multiplex PCR requires a fixed annealing temperature, 37 
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but more complex PCR cycle design can circumvent this. Nevertheless, we were able 1 
to design primers that yielded in 94% of amplicons over 100x coverage (Figure 2B). 2 
We provide all primer sequences (Additional file 2) and an open source optimised 3 
primer library will be growing with an NG-TAS user community.  4 
When using NG-TAS for accurate estimation of VAF, as required to do serial tumour 5 
burden monitoring, our data suggests that at least 10 ng of input cfDNA per replicate 6 
is required. NG-TAS has poor performance with cfDNA input below 5 ng (per replicate), 7 
with amplicon coverage reduced in a stochastic manner, probably due to the limited 8 
availability of template. A suitable alternative protocol for these cases is to generate 9 
an NGS cfDNA library, requiring only 3 ng of cfDNA, and use the library material as 10 
input for NG-TAS.  11 
We applied NG-TAS to a cohort of 30 patients for which both tissue and serial plasma 12 
samples were available. The percentage of mutations identified in tissue and detected 13 
in ctDNA was 100% when the tissue was from a synchronous metastasis biopsy and 14 
58% when the tissue was from the primary tumour. Such agreement is higher than 15 
what recently reported by Chae et al [23]. In their cohort of 45 patients, 60% of tissue 16 
samples were from primary tumours and 58% of the tissues were acquired more than 17 
90 days before ctDNA testing. The FoundationOne panel was used for tissue analysis 18 
and the Guardant360 assay for ctDNA. They detected only 25.6% of tissue mutations 19 
in plasma when evaluating the common regions between the two targeted approaches.  20 
A future development of NG-TAS will be  the use of molecular barcoding, since this 21 
has been shown to improve sensitivity and specificity of amplicon-based deep 22 
sequencing [24]. This will have cost implications, potentially limiting one of the main 23 
advantages of the current NG-TAS protocol. The extra costs would be the result of 24 
generation of barcoded primers. For example, if 96 distinct barcodes are used, the 25 
primer cost will increase around 100 times. However, costs will be significantly diluted 26 
when considering laboratories processing a large number of samples, keeping the 27 
overall cost of NG-TAS within a very reasonable range.  28 
 29 
Conclusions 30 
We have described here the workflow for a highly multiplexed cfDNA deep 31 
sequencing method named NG-TAS. NG-TAS assesses the mutational status of 32 
several genes simultaneously, with high sensitivity (allowing quantification of AF) and 33 
competitive costs, and offers flexibility in the choice of target genes. We have also 34 
shown proof of principle that the monitoring of ctDNA using NG-TAS in metastatic 35 
breast cancer can allow detection of cancer progression earlier than conventional 36 
RECIST measurements.  37 
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Next Generation Targeted Amplicon Sequencing NG-TAS 
Cell Free DNA cfDNA 
Circulating Tumour DNA ctDNA 
Digital PCR dPCR 
Targeted Amplicon Sequencing TAm-Seq 
Next Generation Sequencing NGS 
Formalin Fixed Paraffin Embedded FFPE 
Variant Allele frequency VAF 
Single Nucleotide Variant SNV 
False Positive  FP 
Uracil DNA Glycosylase UDG 
Response Evaluation Criteria in Solid Tumour RECIST 
Computed Tomography CT 
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Table 1. List of genes and regions covered in the panel 1 
Gene Target region Hotspot position No of ampicons 
AKT1 Hotspot 
E17 
AA23 – 59 
AA65 - 94 
4 
BRAF Hotspot V600 1 
Her2 Hotspot 
S310 
AA428 - 438 
AA746 – 797 
AA832 – 986 
14 
HRAS Hotspot 
AA3 – 35 (G12 and 
G13) 
AA49 – 77 (Q61 and 
A66) 
3 
IDH2 Hotspot AA132 - 162 1 
KRAS Hotspot G12 1 
SF3B1 Hotspot K700 1 
ESR1 Part of exons Exon 8 - 10 (LBD) 10 
SMAD4 Part of exons Exon 8 – 12 10 
CDH1 All exons  46 
CDKN1B All exons  9 
FOXA1 All exons  18 
GATA3 All exons  23 
MAP2K4 All exons  22 
MAP3K1 All exons  75 
PIK3CA All exons  59 
PIK3R1 All exons  11 
PTEN All exons  24 
RUNX1 All exons  24 
TP53 All exons  21 
   2 
Field Code Changed
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Table 2. Linear regression analysis for different cfDNA input 1 
 2 
Input DNA R2  
Estimated 
coefficient 
2.5% CI 97.5% CI 
50ng 0.968 1.075 1.018 1.133 
10ng 0.940 1.005 0.930 1.080 
5ng 0.885 0.932 0.832 1.032 
Library 0.964 1.123 1.059 1.187 
 3 
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Table 3: Comparison of different approaches for ctDNA detection 1 
 2 
  3 
 NG-TAS Digital PCR TAm-Seq 
OncomineTM 
Breast cfDNA 
Assay 
Approx. cost per sample 
(GBP) 
3x10 2-3 10 200 
Time (96 reactions) 7h 3h x 2 2 days 2 days 
Number of amplicons 377 1 48 n/a 
Amplicon size <160bp n/a <200bp <170bp 
Number of genes 20 1 (hotspot) 6 10 
Choice of targets Flexible Limited Flexible Limited 
Median depth 3064 770 650 (avg) n/a 
Limit of detection 1-2% >0.1% 1-2% 0.6-0.1% 
Library material as input Yes Not tested Not tested Not tested 
Ideal input 3x10ng 2-5ng 50ng 20ng 
Multiplex 8plex No No n/a 
Number of samples per 
sequence run 
384 n/a 96 12 
Platform 
Fluidigm 
Access Array 
Fluidigm 
qdPCR 
Fluidigm 
Access Array 
Ion Chef 
System 
Sequencing 
Illumina HiSeq 
4000 
n/a Illumina GAIIx  Ion S5/S5XLTM 
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Figure Legends 1 
Figure 1. NG-TAS workflow and alignment pipeline 2 
(A) NG-TAS workflow. Primers were designed and multiplexed for direct amplification 3 
in cfDNA obtained from plasma using Fluidigm Access Array™. The PCR products 4 
were harvested and barcoded in a subsequent PCR reaction, the samples were pooled 5 
and size selected for sequencing on an Illumina Hi-Seq 4000. (B) Schematic 6 
representation of the computational pipeline for reads alignment, filtering and 7 
annotation. 8 
 9 
Figure 2. Optimising targeted deep sequencing by NG-TAS  10 
 (A) Percentage of aligned reads were compared in different samples where a variable 11 
amount of input control genomic DNA was used (range 50 to 0.016ng). The effect of 12 
pre-amplification and Q solutions are shown, red = No Q solution and no pre-13 
amplification step, green = With Q solution and no pre-amplification, blue = No Q 14 
solution and with pre-amplification. (B) Density plot showing the log10 coverage values 15 
for all primers in the 10 ng NA12878 cfDNA sample. The dotted line indicates 100x 16 
coverage; median value for the distribution is 3064x. (C) Coverage heatmap of 17 
individual primers for different amount of input NA12878 cfDNA. For each amount of 18 
input DNA the analysis was performed in triplicate. (D) Distribution of all non-reference 19 
base frequencies across all target regions in the NA12878 dilution series in (C); the 20 
smaller plot on the right is a magnification of the main plot between 0 and 0.01. 21 
 22 
Figure 3. Detection of SNVs in NA12878 cfDNA dilution series 23 
(A) Expected versus observed VAF for 4 SNVs in the NA12878-NA11840 dilution 24 
series starting from 50 ng input DNA (left) and zoom-in for expected VAF <5% (right). 25 
(B) Expected versus observed VAF for 4 SNVs in the NA12878-NA11840 dilution 26 
series starting from 10 ng input DNA (left) and zoom-in for expected VAF <5% (right). 27 
(C) Expected versus observed VAF for 4 SNVs in the NA12878-NA11840 dilution 28 
series starting from 5 ng input DNA (left) and zoom-in for expected VAF <5% (right). 29 
(D) Expected versus observed VAF for 4 SNVs in the NA12878-NA11840 dilution 30 
series starting from post-NGS library input DNA (left) and zoom-in for expected VAF 31 
<5% (right). 32 
 33 
Figure 4. Mutation calling in NA12878 cfDNA dilution series 34 
(A) Schematic overview of the computational pipeline to identify somatic mutations in 35 
NG-TAS data. (B) De novo mutation calling in the NA12878 dilution series was 36 
evaluated for different amounts of input cfDNA. 4 SNVs can potentially be called using 37 
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our panel of 377 amplicons. (C) VAF for all FP calls in the NA12878 dilution series. 1 
The red dashed line represents 5% VAF. 2 
 3 
Figure 5. Validation of NG-TAS performance in clinical plasma samples 4 
(A) The specificity of NG-TAS in clinical samples was estimated using 4 pairs of buffy 5 
coats from the same patients (A, B, C and D). The mutation calling pipeline was applied 6 
using one buffy coat as normal and the other as ‘tumour’ and vice versa. All mutations 7 
called in this setting can be considered FPs. The red line indicates 5% VAF. (B) 8 
Oncoprint summary plot of genes mutated in 24 cases for which both tissue and 9 
plasma samples were tested. The vertical black line separates cases for which the 10 
primary tumour was analysed from cases for which a metastasis biopsy was analysed. 11 
(C-D) Comparison of VAF obtained by NG-TAS and dPCR. (C) In this comparison, four 12 
different hotspot mutations including AKT1 (E17K), ESR1 (D538G), KRAS (G13D) and 13 
PIK3CA (H1047R) identified in multiple plasma samples from 4 distinct patients were 14 
analysed (R2 = 0.64). (D) Two PIK3CA hotspots (H1047R and E545K) were detected 15 
by NG-TAS using NGS library as input material in plasma samples from two distinct 16 
patients. The same mutations were detected using dPCR and a good correlation was 17 
found (R2 = 0.80).  18 
 19 
Figure 6. Monitoring response in metastatic breast cancer patients using NG-20 
TAS 21 
(A) Example of patient monitoring during treatment using direct NG-TAS in ctDNA. 22 
There are four mutations detected in more than one sample: GATA3 (F431fs), PIK3CA 23 
(E542K), CDKN1B (N124fs) and PTEN (137-139del). The mutations called more than 24 
once in the longitudinal samples are shown including tumour and plasma samples. 25 
The arrow indicates the time of the disease considered as RECIST progressive 26 
disease. T indicates tumour samples, and SP indicates screening plasma sample 27 
which was collected prior to the treatment. (B) Example of patient monitoring during 28 
treatment using NGS library material for NG-TAS. This patient had a stable disease 29 
during the whole treatment period. There are three mutations detected, including 30 
MAP3K1 (E303 frame shift), hotspot mutations PIK3CA (E545K) and TP53 (R141H 31 
and P46fs). T indicates tumour samples. 32 
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